The latest market report published by
Credence Research, Inc. “Global Learning
Disability Treatment Market By Therapy (Stimulant Medication, Non
Stimulant Medication, Orton-Gillingham Interventional Therapy, Occupational
Therapy, Assistive Technology), By Indication (Attention Deficit Hyperactivity
Disorder (ADHD), Dyslexia, Dyspraxia, Others) – Growth, Future Prospects &
Competitive Analysis, 2019 – 2027,” the global learning disability
treatment market was valued at US$ 17,418.0 Mn in 2018, and is expected to
reach US$ 30,493.1 Mn by 2027, expanding at a CAGR of 6.5% from 2019 to 2027.
Market Insights
As per the research findings of
American Psychiatrist Association (APA), more than 50% of the children
suffering with learning disability will never be diagnosed in their lifetime.
Effective screening at an early age increases the quality of life of the
patient suffering with learning disability. Government authorities worldwide
are providing adequate financial aid in establishing special school and clinics
to help children and adults suffering with ADHD, dyslexia, dyspraxia and other
mental disabilities.
Browse the full report Learning
Disability Treatment Market – Growth, Future Prospects, Competitive
Analysis, 2019 – 2027 report at https://www.credenceresearch.com/report/learning-disability-treatment-market
Pharmacological treatment module
comprises 80% of the treatment prescribed by psychiatrist worldwide for the
treatment of kids suffering with ADHD and cognitive disability. Stimulants such
as Ritalin, Focalin, etc. are prescribed to improve brain CNS function by
inhibiting the uptake of dopamine and norepinephrine. Non stimulants are
prescribed in patients showing symptoms of anxiety and depression.
Technological advancement in assistive technology in creating software and
application related to CBT and occupational therapy which is utilized by
teachers to help kids with learning disability.
Dyslexia is dominating the indication
segment for learning disability treatment market. 25% of the patients suffering
with ADHD provide symptoms of dyslexia, the core problem is associated with
difficulty in reading, writing and word recognition. Dyscalculia is observed to
a certain level usually in adolescent kids. Comprehensive evaluation test and
critical assessment of underlying language skills results in early diagnosis of
dyslexia and interventional therapy. Attention deficit hyperactivity disorder
(ADHD) has a global prevalence rate of 2.2% with high occurrence in male
population in comparison to female. Combinational therapy of pharmacological drugs
and assistive technology comprising of cognitive behavioral therapy (CBT) is
used for its treatment throughout the globe.
North America is the largest regional
market for learning disability treatment holding a share of 32.5%. The chief
parameters influencing its market growth are rising prevalence of ADHD and
proactive government initiatives to promote awareness and treatment for
children with learning disabilities. Europe has the second largest market share
of 29% on account of rising prevalence of dyslexia among all age groups. Asia
Pacific currently represents 18.5% market share and is keen to register fastest
growth in the near future owing to the rampant growth in special schools to
treat learning disability in children and significant rise in IT healthcare
companies providing assistive technology equipped with occupation therapy and
cognitive behavioral therapy modules.
IT-Healthcare in collaboration with
pharmaceutical companies actively participating in the learning disability
treatment market are CogniFit, Eli Lilly & Company, Forest Laboratories,
Inc., IMSE, Novartis AG, Pfizer, Inc., Shire, Plc., Therapro, Inc., Tumble N’
Dots, Inc. and Texthelp Ltd.
Key Market
Movements:
- Rising prevalence of ADHD worldwide
- Technological advancement in the
assistive technology treatment modules such as occupational therapy and
cognitive behavioral therapy to treat learning disability in children
- Excellent formulation and development of
stimulant and non stimulant medicines to achieve excellent drug efficacy
and minimal adverse effects
Download Free PDF
Sample Request: https://www.credenceresearch.com/sample-request/59705
By Therapy
(2017–2027; US$ Mn)
- Stimulant Medication
- Non Stimulant Medication
- Orton Gillingham Interventional Therapy
- Occupational Therapy
- Assistive Technology
By Indication
(2017–2027; US$ Mn)
- Attention Deficit Hyperactivity Disorder
(ADHD)
- Dyslexia
- Dyspraxia
- Others
By Geography
Segment (2017–2027; US$ Mn)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Do Enquiry before
Buying for research report: https://www.credenceresearch.com/inquiry-before-buying/59705
About Us
Credence
Research is a worldwide market research and counseling firm that serves driving
organizations, governments, non legislative associations, and not-for-benefits.
We offer our customers some assistance with making enduring enhancements to
their execution and understand their most imperative objectives. Over almost a
century, we've manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
Toll-Free (US/CANADA) Ph.: +1-800-361-8290
No comments:
Post a Comment